What does biopharma systems — revenue mean?

This metric represents the total gross sales generated by the BioPharma Systems business unit, which provides drug delivery solutions and pre-filled syringe technologies to pharmaceutical and biotech partners. It serves as a primary indicator of market demand for the company's specialized drug containment and delivery systems.

Becton, Dickinson and Company BDX BioPharma Systems — Revenue

Other segment segments

Medical Essentials

$1.65B—

Interventional

$1.36B+7.4%

Connected Care

$1.12B—

Similar metrics at other companies

PFEBiopharma — Revenues:

$14.16B+5.4%

LHBiopharma Laboratory Services — Revenue

$780.6M+8.2%

STELife Sciences: — Revenue

$145.8M+6.9%

HWK

HWKNPharmaceutical — Revenue

$8.32M+15.1%

VCYTBiopharmaceutical revenue — Total Revenue

$301K-86.9%

CYRXBiologistics Solutions — Revenue

$21.67M+16.9%

Other financials

Income statement

See full

Revenue$4.7B+5.2%

Gross profit$2.2B+15.7%

Operating income$93.0M-75.7%

Net income-$311.0M-201%

EPS (diluted)-$1.11-204%

Balance sheet

See full

Cash & equivalents$1.0B+49.0%

Total debt$14.7B-16.8%

Total equity$24.1B-4.4%

Total assets$50.8B-6.7%

Cash flow

See full

Operating cash flow$671.0M—

CapEx$125.0M+9.6%

Free cash flow$546.0M—

Valuation

See full

Market cap$42.96B-12.6%

Enterprise value$56.65B-14.0%

P/E37.8×+6.7×

P/S2×-0.4×

Profitability

See full

Gross margin46.8%+2.5pp

Operating margin10.4%+0.1pp

Net margin5.3%-2.1pp

FCF margin16.4%—

Returns & leverage

See full

Return on equity4.6%-1.3pp

Debt / equity0.6×-0.1×

Current ratio0.9×-0.2×

Where this comes from

Reported directly by Becton, Dickinson and Company in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Becton, Dickinson and Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Becton, Dickinson and Company's biopharma systems — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Becton, Dickinson and Company's biopharma systems — revenue?: Becton, Dickinson and Company (BDX) reported biopharma systems — revenue of $590M in Q1 2026.
What does biopharma systems — revenue mean?: This metric represents the total gross sales generated by the BioPharma Systems business unit, which provides drug delivery solutions and pre-filled syringe technologies to pharmaceutical and biotech partners. It serves as a primary indicator of market demand for the company's specialized drug containment and delivery systems.